Insmed Incorporated
INSM
Rank in Stocks
#1106
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Share Price
$95.65
Last synced: 2026-10-19
Market Cap
$20.89B
Change (1 day)
-0.65%
Change (1 year)
-43.04%
Country
US
Trade Insmed Incorporated (INSM)
Category
Healthcare
P/B ratio for Insmed Incorporated (INSM)
P/B ratio as of October 2026 TTM: 28.06
According to Insmed Incorporated latest financial reports and stock price the company's current price-to-book ratio (TTM) is 28.06. At the end of 2023 the company had a P/B ratio of -13.11.
P/B ratio history for Insmed Incorporated from 2000 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 28.06 | -29.30% |
| 2024 | 39.69 | -402.68% |
| 2023 | -13.11 | -146.91% |
| 2022 | 27.95 | 275.67% |
| 2021 | 7.44 | -36.83% |
| 2020 | 11.78 | 52.62% |
| 2019 | 7.72 | 59.41% |
| 2018 | 4.84 | -15.80% |
| 2017 | 5.75 | 8.54% |
| 2016 | 5.30 | 55.48% |
| 2015 | 3.41 | -4.67% |
| 2014 | 3.57 | -13.87% |
| 2013 | 4.15 | 182.67% |
| 2012 | 1.47 | 176.73% |
| 2011 | 0.53 | 22.38% |
| 2010 | 0.43 | -45.13% |
| 2009 | 0.79 | -103.91% |
| 2008 | -20.23 | -345.58% |
| 2007 | 8.24 | 36.28% |
| 2006 | 6.04 | -33.73% |
| 2005 | 9.12 | -23.38% |
| 2004 | 11.90 | 195.16% |
| 2003 | 4.03 | 549.88% |
| 2002 | 0.62 | -70.50% |
| 2001 | 2.10 | 220.36% |
| 2000 | 0.66 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -77.72% |
US
|
|
| 13.2547 | -52.76% |
US
|
|
| 4.208 | -85.00% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.97% |
NL
|
